Treatment of Checkpoint Inhibitor–Induced Vitiligo in a Patient with Metastatic Renal Cell Cancer

Abstract

Get full access to this article

View all access options for this article.

References

Sibaud

. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol, 2018; 19(3):345–361.

Xing

, Zhang

, Wang

, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer, 2019; 7(1):341.

Phillips

, Wu

, Hellmann

, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol, 2019; 37(30):2746–2758.

Lolli

, Medri

, Ricci

, et al. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. Medicine (Baltimore), 2018; 97(52):e13810.

Grimes

, Miller

. Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Womens Dermatol, 2018; 4(1):32–37.